Peter Hecht, Cyclerion Therapeutics CEO
Hard pressed for cash, Cyclerion looks for help funding rare disease drug
Cyclerion Therapeutics may have the design of a Phase IIb study ready to go, but it’s scrambling for a way to fund it.
The company …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
